Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890506) titled 'Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Condition:
BTC
Intervention:
Drug: chidamide+benmelstobart+nab-paclitaxel+SBRT
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 1, 2026
Target Sample Size: 41
Countries of Recruitment:
China
To know...